Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
e.l.f. Beauty Q4 FY2026 Earnings Call - Core Brand Growth Slows as Rhode Accelerates; Management Takes Pricing and Innovation Actions
e.l.f. Beauty closed fiscal 2026 with 25% net sales growth and 13% adjusted EBITDA growth, marking its 29th consecutive quarter of top-line expansion. The acquisition of Rhode accelerated growth, cont...
- e.l.f. Beauty delivered 25% net sales growth and 13% adjusted EBITDA growth for fiscal 2026, marking its 29th consecutive quarter of net sales expansion.
- The acquisition of Rhode contributed approximately $390 million in annualized net sales, growing over 80% year-over-year and becoming Sephora’s number one beauty brand in North America.
- Core e.l.f. brand growth moderated, with Q4 organic sales rising just 1% and unit volumes declining 5%, reflecting softer spring innovation and the impact of a recent dollar price increase.
- +7 more takeaways
Streamex Corp Q1 2026 Earnings Call - Debt Retired, Dividends Paid, and Institutional Partnerships Locked In
Streamex Corp emerged from a preparation phase into proof of concept in Q1 2026. The company launched its first tokenized gold product, GLDY, paid its first two dividends, and completely retired its $...
- Streamex launched GLDY, its first tokenized yield-bearing gold product, and paid its first two dividends totaling 10.48 ounces of gold to holders.
- The company retired all $50 million in convertible debenture debt, resulting in a clean balance sheet with zero debt and $45.85 million in cash and investments.
- Q1 2026 GAAP loss of $48.6 million was heavily impacted by $25.4 million in non-cash stock-based compensation and $12.2 million in non-cash debt retirement costs.
- +7 more takeaways
Tucows Inc. Q1 2026 Earnings Call - CEO Outlines Capital-Light Pivot and Strategic Portfolio Review
Tucows is executing a decisive pivot toward a capital-light, recurring-revenue model, with management explicitly evaluating each business unit for strategic fit and shareholder value creation. CEO Dav...
- Tucows is explicitly transitioning to a capital-light, lean operating model centered on recurring revenue, strong retention, and platform economics.
- Wavelo receives targeted investments in product and go-to-market, but these are strictly tied to bookings conversion and long-term value creation metrics, not open-ended spending.
- Ting’s strategic path likely involves a sale or partnership with a larger operator possessing the capital and scale to drive profitability.
- +7 more takeaways
Belite Bio Q1 2026 Earnings Call - NDA Rolling Submission Initiated for Tinlarebant in Stargardt Disease
Belite Bio is transitioning from a clinical-stage biotech to a commercial entity as it pushes Tinlarebant toward FDA approval for Stargardt disease. The company initiated a rolling NDA submission in A...
- Belite Bio initiated a rolling NDA submission to the FDA for Tinlarebant in Stargardt disease in April, aiming for completion by Q2 2026.
- The company completed enrollment in the DRAGON II phase II/III trial for Japan, enrolling 73 subjects aged 12 to 20.
- Q1 2026 R&D expenses rose to $15.7 million from $9.4 million, driven by DRAGON II trial costs and manufacturing.
- +7 more takeaways
PAVmed Q3 2026 Earnings Call - Restructured Balance Sheet Paves Way for Aggressive Life Sciences Expansion
PAVmed has officially completed a complex two-year restructuring, effectively wiping its balance sheet clean of legacy preferred equity and convertible debt. The move replaces that friction with a $30...
- PAVmed has successfully concluded a two-year restructuring, fully retiring its Series C convertible preferred stock and legacy convertible debt to present a clean balance sheet.
- The company secured $30 million in a Series D preferred offering, which was subsequently converted to common stock, alongside a $15 million senior secured note maturing in February 2029.
- Cash on hand stands at $6.5 million as of March 31, 2026, though this figure excludes the potential $30 million in proceeds from warrants exercisable upon a positive EsoGuard LCD.
- +7 more takeaways
Cadre Holdings Q1 2026 Earnings Call - Record Backlog and M&A Momentum Drive 20%+ Growth Outlook
Cadre Holdings delivered a strong first quarter in 2026, with net sales rising 19% year-over-year to $155.4 million and a record backlog of $355 million. The growth was fueled by robust demand across ...
- Net sales grew 19% year-over-year to $155.4 million, driven by recurring demand for mission-critical safety products across law enforcement, military, and nuclear markets.
- Record order backlog reached $355 million, up $166 million from Q4 2025, signaling strong demand and providing visibility into 2026 revenue.
- Cadre completed two acquisitions in 2026: TYR Tactical ($175 million) and Alien Gear Holsters ($10 million), expanding its product portfolio and market presence.
- +7 more takeaways
RBC Bearings Q4 FY2026 Earnings Call - A&D Momentum Masks Industrial Softness
RBC Bearings delivered a record fiscal fourth quarter, with net sales surging 18.3% year-over-year to $518 million, driven by a 41.2% jump in its aerospace and defense segment. The company’s backlog h...
- RBC Bearings reported record Q4 FY2026 net sales of $518 million, up 18.3% year-over-year, driven by a 41.2% surge in its aerospace and defense segment.
- Adjusted diluted EPS rose 27.9% to $3.62, while adjusted EBITDA grew 21% to $168.9 million, reflecting strong operational leverage.
- The aerospace and defense backlog expanded to $2.3 billion, supported by robust demand in commercial aircraft, defense missiles, and submarine programs.
- +12 more takeaways
Venu Holding Corporation Q1 2026 Earnings Call - New Asset Class of Live Entertainment Venues Gains Momentum
Venu Holding Corporation reported a strong start to fiscal 2026, with total assets growing 25% to $461 million and a successful $86.25 million capital raise despite market volatility. The company is a...
- Total assets grew 25% to $461 million, though GAAP accounting excludes the value of municipality-contributed real estate; an independent appraisal values the portfolio at $1.24 billion on an as-completed basis.
- Completed a $86.25 million equity raise in March, demonstrating investor conviction despite market volatility, with net proceeds of $80.1 million.
- Revenue increased 11% year-over-year to $3.9 million for Q1 2026, reflecting early-stage growth from operational venues and hospitality services.
- +7 more takeaways
National Grid FY 2026 Earnings Call - CEO Unveils 70 Billion Capital Program and AI-Driven Grid Transformation
National Grid delivered strong FY 2026 results, with underlying operating profit rising to GBP 5.7 billion and underlying EPS growing 8% at constant currency. The company announced a step-up in capita...
- Underlying operating profit rose to GBP 5.7 billion, and underlying EPS grew 8% at constant currency, meeting guidance.
- Capital expenditure increased by over 20% to GBP 11.6 billion, signaling a major ramp-up in infrastructure investment.
- New CEO Zoë Winters introduced a five-year framework targeting at least GBP 70 billion in total investment.
- +7 more takeaways
Evogene Q1 2026 Earnings Call - AI-Driven Drug Discovery Gains Momentum While AgChem Partnership Terminates
Evogene reported a rough first quarter in 2026, posting a $5.9 million net loss driven by a steep drop in revenue and non-cash financing expenses tied to warrant accounting. Revenue fell to just $0.3 ...
- Evogene's Q1 2026 net loss widened to $5.9 million from $3.0 million in Q1 2025, primarily due to a $2.0 million revenue decline and $2.7 million in net financing expenses.
- Revenue collapsed to $0.3 million from $2.3 million year-over-year, driven by the near-total disappearance of seed sales from the Casterra subsidiary.
- The company is liquidating non-core subsidiaries: Lavie Bio operations ended in Q1 2026 with a $4.25 million dividend distribution, and Biomica approved a $2.7 million shareholder distribution.
- +7 more takeaways